A U.S.-based venture capital firm invests in early-stage neuropsychiatric and mental health opportunities. The firm primarily invests from Pre-Seed through Series A, with initial checks typically ranging from $50K–$1M and capacity for follow-on investment. The firm is comfortable serving as the first institutional investor and can lead or co-invest alongside other investors. Investments may be structured through traditional equity financings or SAFEs. The firm primarily targets U.S.-based companies while remaining open to opportunities globally.  

The firm invests in therapeutics and technologies addressing neuropsychiatric conditions, mental health, and general wellness. Areas of interest include psychedelic medicine, brain-computer interfaces, therapeutic platforms, precision diagnostics, and other technologies addressing neurological and psychiatric conditions. For biotechnology and therapeutics opportunities, the firm generally prefers assets that are at or approaching the IND stage. For medical technology opportunities, the firm is comfortable engaging earlier in the development process.  

From a company and management team perspective, the firm does not impose strict requirements regarding team composition. The firm has a strong preference for founders with prior pharmaceutical or biotechnology industry experience or a demonstrated track record of successful entrepreneurship. The firm may seek a board seat or observer position on a case-by-case basis and takes a flexible approach to governance depending on the company’s stage and financing structure. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a U.S.-based venture capital investor focused on Seed through growth-stage deep-tech companies, including opportunities across healthcare. The firm invests through direct and special-purpose investment structures and can access matching capital of up to $10M for qualifying companies willing to establish operations in a designated U.S. innovation ecosystem. The firm primarily targets companies with differentiated technologies and evidence of meaningful technical or commercial validation. 

Within healthcare, the firm focuses primarily on healthtech, including digital health and medical technology. For therapeutics, the firm selectively considers companies addressing compelling disease areas through novel technologies and generally requires programs to have completed Phase I development or otherwise achieved substantial technical and clinical de-risking. For digital health opportunities, the firm requires demonstrated customer traction and a minimum level of commercial revenue. Pre-revenue pharmaceutical companies may be considered when meaningful alternative indicators of traction and validation can be demonstrated.  

From a company and management team perspective, the firm seeks companies that can demonstrate clear evidence of technology validation, market traction, or clinical de-risking appropriate to their sector and development stage. The firm takes an active governance approach and requires a board seat as part of its investment. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a U.S.-focused therapeutics venture studio that translates academic discoveries into venture- and pharmaceutical-ready drug development programs. Backed by a specialist life sciences investor and supported by strategic industry partners, the firm combines company creation, scientific development, and very early-stage investment capabilities. The firm works closely with academic institutions to identify promising discoveries, form new biotechnology companies, and advance programs toward milestones suitable for institutional financing. The firm currently focuses primarily on U.S.-based opportunities while expanding its activities into the UK and Israel.  

The firm invests exclusively in traditional therapeutics and targets programs at the earliest stages of development, with clinical-stage assets generally considered too advanced for its model. The firm is broadly modality-agnostic but has a preference for established therapeutic modalities such as small molecules and biologics. Areas of particular interest include oncology, kidney disease, fibrosis, immunology and inflammation, and neuroscience/CNS. The firm remains open to other indications when programs address compelling unmet medical needs and have substantial commercial potential.  

From a company and management team perspective, the firm does not impose strict requirements and is specifically structured to work with academic founders before a conventional management team has been assembled. Academic investigators may serve as scientific founders while the firm’s internal leadership and development team provide interim executive and operational support. The firm works hands-on to advance scientific programs, establish new companies, and prepare them for subsequent institutional financing and continued development. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

A corporate venture capital arm of a global pharmaceutical company is actively identifying next-generation healthcare technologies and emerging growth opportunities. Operating independently from the parent company’s traditional business development activities, the firm takes a primarily financially driven investment approach. The firm focuses on Seed, early-, and mid-stage companies while remaining open to select Pre-Seed opportunities.  

The firm invests globally across Asia, North America, and Europe, with investment sizes tailored to each company’s stage and financing needs. The firm invests across three broad themes: restoration and enhancement of human biological functions, infectious disease eradication, and technologies that strengthen the healthcare value chain. The firm’s mandate extends beyond therapeutics to include enabling technologies, healthcare infrastructure, and platform innovations that could shape future healthcare delivery and development. The firm seeks opportunities both adjacent to and beyond its parent company’s existing businesses, prioritizing breakthrough science, significant unmet medical needs, and technologies with substantial long-term growth potential.  

From a company and management team perspective, the firm seeks scientifically differentiated technologies and founders with the potential to build sustainable healthcare businesses. The firm does not require licensing rights, acquisition options, commercialization agreements, or other strategic rights as a condition of investment. The firm can provide portfolio companies with access to pharmaceutical R&D expertise, development capabilities, industry experience, and a global network. Strategic collaborations, licensing, co-development, or other transactions may be explored separately as portfolio companies mature when mutually beneficial. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

An early-stage venture capital investor is focused on globally scalable technology companies with connections to Southeast Asia and the United States. The firm primarily invests at the Pre-Seed, Seed, and Pre-Series A stages, typically deploying approximately $150K–$1M per company and generally targeting ownership positions of 5–15%. A meaningful portion of the firm’s capital is allocated to life sciences and healthcare innovation. The firm leverages technical expertise, entrepreneurial experience, and international operating networks to support early-stage companies pursuing global growth. 

Within life sciences and healthcare, the firm focuses on techbio and technology-enabled healthcare innovation. Areas of interest include computational biology, artificial intelligence and machine learning, protein and RNA technologies, gene editing and CRISPR, precision therapeutics, AI-enabled drug discovery, biomaterials, regenerative medicine, tissue engineering, synthetic biology, screening and diagnostics, digital health, healthcare analytics, and health data infrastructure. The firm is comfortable investing at very early stages, including preclinical and research-stage opportunities, and is generally indication-agnostic, with additional interest in neurotechnology and neuroscience. 

From a company and management team perspective, the firm seeks ambitious founders and technically strong teams developing differentiated intellectual property and defensible technology platforms. The firm can lead or co-invest and generally seeks board participation when leading a financing. The firm actively supports portfolio companies with technology strategy, business scaling, international expansion, recruiting, and future fundraising through its network of operators, technologists, and industry experts. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is a U.S.-based healthcare investment manager focused exclusively on biotechnology and biopharmaceutical companies. The firm invests across both public and private markets and has more than two decades of experience investing in life sciences. Through its dedicated private investment strategy, the firm supports emerging biotechnology companies from Seed through Series B, with initial investments typically averaging approximately $10M and significant capacity for follow-on participation. Investments are primarily structured as equity, although convertible instruments may be considered for select Seed-stage opportunities. The firm primarily targets companies in the United States and Europe. 

The firm invests exclusively in therapeutics and is broadly agnostic across modalities and disease areas. The firm evaluates small molecules, biologics, antibodies, RNA therapeutics, cell and gene therapies, and other emerging therapeutic platforms. Areas of interest include oncology, immunology, rare diseases, metabolic disorders, and other indications characterized by significant unmet medical need. The firm is comfortable investing from the preclinical stage onward and prioritizes differentiated science, strong biological rationale, and programs capable of generating meaningful clinical value. 

From a company and management team perspective, the firm seeks strong scientific founders and experienced leadership teams capable of advancing complex therapeutic programs through key clinical and value-inflection milestones. The firm can lead, co-lead, or participate in investment syndicates and may seek board representation or observer rights. The firm takes an active approach to portfolio support, working with management on financing strategy, clinical development, business development, and long-term company building. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The firm is the corporate venture capital arm of a diversified global company with substantial healthcare operations. The firm operates through an evergreen investment model and invests globally, with particular activity across North America, Europe, and Asia. Initial investments typically range from approximately $1M–$3M, with the capacity to invest $5M or more over the life of a portfolio company. The firm pursues strategic investments that complement its parent organization’s healthcare businesses and long-term innovation priorities. 

The firm invests across pharmaceuticals, medical devices, diagnostics, digital health, bioprocessing, and other enabling healthcare technologies. Areas of particular interest include pain management, critical care, kidney disease, musculoskeletal disorders, drug delivery, patient monitoring, digital therapeutics, and technologies that improve healthcare delivery and clinical outcomes. The firm is generally stage-agnostic but tends to favor opportunities demonstrating meaningful technical validation, preclinical proof-of-concept, or early clinical data. The firm evaluates investments partly based on their potential strategic relevance to its broader healthcare capabilities. 

From a company and management team perspective, the firm invests exclusively in private companies and is comfortable partnering with early-stage teams that are still developing their leadership and operational capabilities. The firm takes a collaborative, strategic approach and can provide access to global healthcare expertise, technical and manufacturing resources, and commercial relationships. The firm generally seeks board participation or observer rights and actively supports portfolio companies with business development, strategic partnerships, product development, and long-term growth. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.